Jon Hyman MD
  • BEST ORTHOPEDIC TRAINING
  • HARVARD MEDICAL SCHOOL
  • Stanford University
  • Stanford University


Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain Nasdaq:FLXN

Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain Nasdaq:FLXN
There is a newly FDA approved, non-opioid drug on the market for those who suffer with osteoarthritic knee pain. Researchers and scientists are hailing its arrival as a non-surgical advancement in the struggle to relieve a growing number of patients, both old and young, from the debilitating effects of chronic knee pain.

There is a newly FDA approved, non-opioid drug on the market for those who suffer with osteoarthritic knee pain. Researchers and scientists are hailing its arrival as a non-surgical advancement in the struggle to relieve a growing number of patients, both old and young, from the debilitating effects of chronic knee pain.  Successfully conducted studies confirm these findings, a boon to both patients and practitioners.  The drug, commercially known as ZILRETTA, will be marketed this Fall. Administered by injection this time-released medicine promises real relief for extended periods. 

Read more


  • Tucker Office Location:1462 Montreal Rd WEST Suite 101,
    Tucker, GA 30084
    Phone: (770) 363-8770

  • Buckhead Office Location:3200 Downwood Circle, Suite 340
    Atlanta, GA 30327
    Phone: (770) 363-8770

AAOS The American Board of Orthopaedic Surgery EMORY harvard Hospital for Special Surgery Stanford University Atlanta Magazine Top Doctocs Castle Connolly Top Doctocs